Consun Pharmaceutical Group Limited (HKG:1681)
17.39
+0.89 (5.39%)
At close: Mar 27, 2026
HKG:1681 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,234 | 2,908 | 2,748 | 2,450 | 2,196 |
Short-Term Investments | 2,669 | 958 | 834.94 | 589.17 | 230 |
Cash & Short-Term Investments | 3,903 | 3,866 | 3,583 | 3,039 | 2,426 |
Cash Growth | 0.98% | 7.88% | 17.89% | 25.26% | 25.05% |
Accounts Receivable | 354.54 | 297.57 | 255.84 | 259.56 | 351.23 |
Other Receivables | - | 72.55 | 54.13 | 36.1 | 18.34 |
Receivables | 354.54 | 370.12 | 309.97 | 295.66 | 369.57 |
Inventory | 271.41 | 315.51 | 384.91 | 287.66 | 257.62 |
Restricted Cash | 42.9 | - | - | - | 2.32 |
Other Current Assets | 32.42 | - | - | - | - |
Total Current Assets | 4,605 | 4,551 | 4,278 | 3,623 | 3,056 |
Property, Plant & Equipment | 921.17 | 925.54 | 863.71 | 875 | 858.45 |
Long-Term Investments | 513.83 | 29.08 | 9.23 | 6.5 | - |
Other Intangible Assets | 265.61 | 268.96 | 283.14 | 311.9 | 341.66 |
Long-Term Deferred Tax Assets | 41.95 | 12.52 | 17.84 | 36.43 | 46.86 |
Other Long-Term Assets | 62.71 | 65.67 | 55.99 | 39.87 | 59.94 |
Total Assets | 6,410 | 5,853 | 5,508 | 4,892 | 4,363 |
Accounts Payable | 1,188 | 75.64 | 83.1 | 59.89 | 66.64 |
Accrued Expenses | - | 736.12 | 638.76 | 566.13 | 465.53 |
Current Portion of Long-Term Debt | 200 | 253.34 | 503.42 | 450.52 | 599.3 |
Current Portion of Leases | 9.71 | 6.42 | 4.22 | 3.71 | 3.12 |
Current Income Taxes Payable | 31.51 | 47.63 | 43.38 | 32.89 | 2.54 |
Current Unearned Revenue | 1.34 | 60.82 | 17.56 | 39.98 | 21.21 |
Other Current Liabilities | - | 190.83 | 204.57 | 197.37 | 199.07 |
Total Current Liabilities | 1,430 | 1,371 | 1,495 | 1,350 | 1,357 |
Long-Term Leases | 3.21 | 7.41 | 3.9 | 5.95 | 8.55 |
Long-Term Unearned Revenue | 12.9 | 14.64 | 19.18 | 18.93 | 16.7 |
Long-Term Deferred Tax Liabilities | 125.72 | 67.19 | 71.21 | 78.01 | 69.3 |
Total Liabilities | 1,572 | 1,460 | 1,589 | 1,453 | 1,452 |
Common Stock | 67.23 | 67.31 | 63.81 | 63.45 | 64.8 |
Additional Paid-In Capital | - | 216.46 | 18.15 | - | 19.79 |
Retained Earnings | - | 3,650 | 3,381 | 2,913 | 2,393 |
Treasury Stock | - | - | -83.17 | -83.17 | -113.32 |
Comprehensive Income & Other | 4,468 | 163.67 | 247.15 | 251.7 | 253.89 |
Total Common Equity | 4,535 | 4,098 | 3,627 | 3,145 | 2,618 |
Minority Interest | 302.84 | 295.45 | 292.21 | 293.87 | 293.08 |
Shareholders' Equity | 4,838 | 4,393 | 3,919 | 3,439 | 2,911 |
Total Liabilities & Equity | 6,410 | 5,853 | 5,508 | 4,892 | 4,363 |
Total Debt | 212.92 | 267.17 | 511.53 | 460.18 | 610.97 |
Net Cash (Debt) | 3,691 | 3,599 | 3,072 | 2,579 | 1,815 |
Net Cash Growth | 2.56% | 17.15% | 19.10% | 42.08% | 30.52% |
Net Cash Per Share | 4.31 | 4.32 | 3.84 | 3.26 | 2.26 |
Filing Date Shares Outstanding | 847.34 | 830.83 | 792.43 | 788.39 | 805.64 |
Total Common Shares Outstanding | 847.34 | 830.83 | 792.43 | 788.39 | 805.64 |
Working Capital | 3,174 | 3,181 | 2,783 | 2,272 | 1,698 |
Book Value Per Share | 5.35 | 4.93 | 4.58 | 3.99 | 3.25 |
Tangible Book Value | 4,269 | 3,829 | 3,343 | 2,833 | 2,276 |
Tangible Book Value Per Share | 5.04 | 4.61 | 4.22 | 3.59 | 2.83 |
Buildings | - | 399.2 | 338.28 | 334.82 | 334.1 |
Machinery | - | 363.52 | 324.86 | 302.16 | 282.15 |
Construction In Progress | - | 412.24 | 416.43 | 416.01 | 381.67 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.